Intellia Therapeutics Announces New Positive Clinical Data from Phase 1 Study of NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema (HAE)
Source: Nasdaq GlobeNewswire / 11 Jun 2023 08:30:00 America/New_York